AVR
Anteris Technologies Global Corp.
AVR trails on the overall score without a compensating advantage in the available component scores.
OSCR
Oscar Health, Inc.
OSCR has the edge over AVR overall, supported by stronger fundamentals and lower modeled downside.
AVR Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
AVR's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
AVR PE Valuation
AVR has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
AVR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect AVR's losses to shrink, with revenue declining. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
AVR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.60 | +$1.03 |
| Q2 2026 | -$1.94 | +$0.68 |
| Q1 2026 | -$2.22 | +$0.34 |
| Q4 2025 | -$2.55 | -$0.15 |
| Q3 2025 | -$2.63 | -$0.66 |
| Q2 2025 | -$2.62 | -$0.96 |
| Q1 2025 | -$2.56 | -$1.12 |
| Q4 2024 | -$2.40 | -$1.12 |
AVR is still losing money, but less than at its worst: $1.60 per share over the past year, against $2.63 at its worst in late 2025.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over AVR on earnings quality, reporting a profit while its opponent remains loss making.
AVR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $519K | +21% |
| Q2 2026 | $1M | +63% |
| Q1 2026 | $494K | -11% |
| Q4 2025 | $310K | -42% |
| Q3 2025 | $429K | -44% |
| Q2 2025 | $618K | -2.1% |
| Q1 2025 | $556K | -27% |
| Q4 2024 | $536.1K | -1.5% |
AVR's revenue is recovering but still below its 2023 peak: $519,000 last quarter, up 21% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -5750% | -560 points |
| Q2 2026 | -3072% | +307 points |
| Q1 2026 | -4860% | -943 points |
| Q4 2025 | -9344% | -5415 points |
| Q3 2025 | -5190% | -2344 points |
| Q2 2025 | -3379% | -391 points |
| Q1 2025 | -3917% | -1596 points |
| Q4 2024 | -3929% | -1010 points |
AVR's operating margin was −5750% last quarter, down 560 points from the same quarter a year ago, near the bottom of its range since 2023.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over AVR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over AVR on profitability, with a higher operating margin.
AVR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$24.3M | -$5.3M |
| Q2 2026 | -$21.4M | -$1.4M |
| Q1 2026 | -$28.8M | -$7.1M |
| Q4 2025 | -$18.9M | -$323.6K |
| Q3 2025 | -$19M | -$4.4M |
| Q2 2025 | -$20.1M | -$6.1M |
| Q1 2025 | -$21.7M | -$5.5M |
| Q4 2024 | -$18.6M | -$10.2M |
AVR has burned cash in almost every quarter: −$93M over the past year, against −$79M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over AVR on cash generation, producing positive trailing cash flow while its opponent burns cash.
AVR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +120K shares |
| 1 year | +170% | +61.4M shares |
| 3 years | +171% | +61.5M shares |
AVR has 97M diluted shares, up 170% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over AVR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
AVR Net Leverage
AVR's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
AVR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.8 | Neutral |
| Stochastic | 11.5 | Oversold |
AVR's weekly RSI is 39 (neutral) and its Stochastic is 12 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
AVR PE vs Healthcare Sector
AVR has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
AVR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.49 | 9.7% below |
| 20 week MA | $7.90 | 26% below |
| 50 week MA | $7.02 | 17% below |
| 100 week MA | $5.87 | 0.2% below |
OSCR has stronger trend alignment. AVR is above 0 of 4 weekly averages versus OSCR above 5 of 5.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
AVR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $5.60 | $5.61 | +0.2% |
| 2025 | $5.61 | $5.59 | -0.4% |
| 2026 YTD | $5.59 | $5.86 | +4.8% |
AVR has finished lower in one of the last two years. It's up 4.8% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over AVR on returns for 2026, with the stronger performance.